ACS Medicinal Chemistry Letters
Letter
Activating Mutations: Interim Results. 16th Congress of the European
Hematology Association (London, England, 2011).
(8) Pixley, F. J.; Stanley, E. R. CSF-1 Regulation of the Wandering
Macrophage: Complexity in Action. Trends Cell Biol. 2004, 14, 628−
638.
studies. This material is available free of charge via the Internet
AUTHOR INFORMATION
Corresponding Author
■
(9) Chitu, V.; Stanley, E. R. Colony-stimulating Factor-1 in Immunity
and Inflammation. Curr. Opin. Immunol. 2006, 18, 39−48.
(10) Douglass, T. G.; Driggers, L.; Zhang, J. G.; Hoa, N.; Delgado,
C.; Williams, C. C.; Dan, Q.; Sanchez, R.; Jeffes, E. W. B.; Wepsic, H.
T.; Myers, M. P.; Koths, K.; Jadus, M. R. Macrophage Colony
Stimulating Factor: Not Just for Macrophages Anymore! A Gateway
into Complex Biologies. Int. Immunopharmacol. 2008, 8, 1354−1376.
(11) Teitelbaum, S. L. Osteoclasts: What Do They Do and How Do
They Do it? Am. J. Pathol. 2007, 170, 427−435.
(12) Bingle, L.; Brown, N. J.; Lewis, C. E. The Role of Tumour-
Associated Macrophages in Tumour Progression: Implications for
New Anticancer Therapies. J. Pathol. 2002, 196, 254−265.
(13) Priceman, S. J.; Sung, J. L.; Shaposhnik, Z.; Burton, J. B.; Torres-
Collado, A. X.; Moughon, D. L.; Johnson, M.; Lusis, A. J.; Cohen, D.
A.; Iruela-Arispe, M. L.; Wu, L. Targeting Distinct Tumor-Infiltrating
Myeloid Cells by Inhibiting CSF-1 Receptor: Combating Tumor
Evasion of Antiangiogenic Therapy. Blood 2010, 115, 1461−1471.
(14) Manthey, C. L.; Johnson, D. L.; Illig, C. R.; Tuman, R. W.;
Zhou, Z.; Baker, J. F.; Chaikin, M. A.; Donatelli, R. R.; Franks, C. F.;
Zeng, L.; Crysler, C.; Chen, Y.; Yurkow, E. J.; Boczon, L.; Meegalla, S.
K.; Wilson, K. J.; Wall, M. J.; Chen, J.; Ballentine, S. K.; Ott, H.;
Baumann, C.; Lawrence, D.; Tomczuk, B. E.; Molloy, C. J. JNJ-
28312141, a Novel Orally Active Colony-Stimulating Factor-1
Receptor/FMS-Related Receptor Tyrosine Kinase-3 Receptor Ty-
rosine Kinase Inhibitor with Potential Utility in Solid Tumors, Bone
Metastases, and Acute Myeloid Leukemia. Mol. Cancer Ther. 2009, 8,
3151−3161.
Present Addresses
#Merck Research Laboratories, West Point, Pennsylvania,
15001.
○Astute Medical, San Diego, California 92121.
∇Dart Neuroscience LLC, San Diego, California, 92121.
@Cytokinetics, South San Francisco, California, 94080.
$Celgene Corporation, San Diego, California 92121.
+Aragon Pharmaceuticals, San Diego, California 92130.
βDiscoveRx, San Diego, California 92121.
Author Contributions
The manuscript was written through contributions of all
authors. All authors have given approval to the final version of
the manuscript.
Notes
The authors declare no competing financial interest.
ACKNOWLEDGMENTS
■
We thank the KinomeScan group at Ambit Biosciences (now a
division of DiscoveRx) for generating the binding Kd values and
kinase specificity scores.
ABBREVIATIONS
■
(15) Kitaura, H.; Zhou, P.; Kim, H.-J.; Novack, D. V.; Ross, F. P.;
Teitelbaum, S. L. M-CSF Mediates TNF-Induced Inflammatory
Osteolysis. J. Clin. Invest. 2005, 115, 3418−3427.
(16) Weitzmann, M. N.; Cenci, S.; Rifas, L.; Brown, C.; Pacifici, R.
IL-7 Stimulates Osteoclast Formation by Upregulating the T-Cell
Production of Soluble Osteoclastogenic Cytokines. Blood 2000, 96,
1873−1878.
RTK, receptor tyrosine kinase; PDGFR, platelet-derived
growth factor; CSF1R, colony-stimulating factor-1 receptor;
FMS, feline McDonough sarcoma; FLT3, FMS-like tyrosine
kinase 3; KIT, stem cell factor receptor; AML, acute myeloid
leukemia; ITD, internal tandem duplication; M-CSF, macro-
phage colony-stimulating factor; TAM, tumor-associated
macrophage; ATP, adenosine triphosphate; PD, pharmacody-
namic; CIA, collagen-induced arthritis
(17) Campbell, I. K.; Rich, M. J.; Bischof, R. J.; Hamilton, J. A. The
Colony-Stimulating Factors and Collagen-Induced Arthritis: Exacer-
bation of Disease by M-CSF and G-CSF and Requirement for
Endogenous M-CSF. J. Leukocyte Biol. 2000, 68, 144−150.
(18) Conway, J. G.; Pink, H.; Bergquist, M. L.; Han, B.; Depee, S.;
Tadepalli, S.; Lin, P.; Crumrine, R. C.; Binz, J.; Clark, R. L.; Selph, J.
L.; Stimpson, S. A.; Hutchins, J. T.; Chamberlain, S. D.; Brodie, T. A.
Effects of the cFMS Kinase Inhibitor 5-(3-Methoxy-4-((4-
methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine (GW2580) in
Normal and Arthritic Rats. J. Pharmacol. Exp. Ther. 2008, 326, 41−50.
(19) Illig, C. R.; Manthey, C. L.; Wall, M. J.; Meegalla, S. K.; Chen, J.;
Wilson, K. J.; Ballentine, S. K.; DesJarlais, R. L.; Schubert, C.; Crysler,
C. S.; Chen, Y.; Molloy, C. J.; Chaikin, M. A.; Donatelli, R. R.; Yurkow,
E.; Zhou, Z.; Player, M. R.; Tomczuk, B. E. Optimization of a Potent
Class of Arylamide Colony-Stimulating Factor-1 Receptor Inhibitors
Leading to Anti-Inflammatory Clinical Candidate 4-Cyano-n-[2-(1-
cyclohexen-1-yl)-4-[1-[(dimethylamino)-acetyl]-4-piperidinyl]-
phenyl]-1h-imidazole-2-carboxamide (JNJ-28312141). J. Med. Chem.
2011, 54, 7860−7883.
(21) Davis, M. I.; Hunt, J. P.; Herrgard., S.; Ciceri, P.; Wodicka, L.
M.; Pallares, G.; Hocker, M.; Treiber, D. K.; Zarrinkar, P. P.
Comprehensive Analysis of Kinase Inhibitor Selectivity. Nat.
Biotechnol. 2011, 29, 1046−1051 and references cited therein.
(22) Patel, H. K.; Grotzfeld, R. M.; Lai, A. G.; Mehta, S. A.; Milanov,
Z. V.; Chao, Q.; Sprankle, K. G.; Carter, T. A.; Velasco, A. M.; Fabian,
M. A.; James, J.; Treiber, D. T.; Lockhart, D. J.; Zarrinkar, P. P.;
Bhagwat, S. S. Arylcarboxyamino-Substituted Diaryl Ureas as Potent
and Selective FLT3 Inhibitors. Bioorg. Med. Chem. Lett. 2009, 19,
5182−5185.
REFERENCES
■
(1) Zwick, E.; Bange, J.; Ullrich, A. Receptor Tyrosine Kinase
Signalling as a Target for Cancer Intervention Strategies. Endocr. Relat.
Cancer 2001, 8, 161−173.
(2) Schlessinger, J. Cell Signaling by Receptor Tyrosine Kinases. Cell
2000, 103, 211−225.
(3) Roskoski, R., Jr. Sunitinib: A VEGF and PDGF Receptor Protein
Kinase and Angiogenesis Inhibitor. Biochem. Biophys. Res. Commun.
2007, 356, 323−328.
(4) Abu-Duhier, F. M.; Goodeve, A. C.; Care, R. S.; Gari, M.; Wilson,
G. A.; Peake, I. R.; Reilly, J. T. Mutational Analysis of Class III
Receptor Tyrosine Kinases (C-KIT, C-FMS, FLT3) in Idiopathic
Myelofibrosis. Br. J. Hemaetol. 2003, 120, 464−470.
(5) Gilliland, D. G.; Griffin, J. D. The Roles of FLT3 in
Hematopoiesis and Leukemia. Blood 2002, 100, 1532−1542.
(6) Zarrinkar, P. P.; Gunawardane, R. N.; Cramer, M. D.; Gardner,
M. F.; Brigham, D.; Belli, B.; Karaman, M. W.; Pratz, K. W.; Pallares,
G.; Chao, Q.; Sprankle, K. G.; Patel, H. K.; Levis, M.; Armstrong, R.
C.; James, J.; Bhagwat, S. S. AC220 is a Uniquely Potent and Selective
Inhibitor of FLT3 for the Treatment of Acute Myeloid Leukemia
(AML). Blood 2009, 114, 2984−2992.
(7) Cortes, J.; Perl, A.; Smith, C.; Kovacsovics, T.; Dombret, H.;
Dohner, H.; Steffen, B.; Pigneux, A.; Rousselot, P.; Krauter, J.;
Martinelli, G.; Estey, E.; Burnett, A.; Ho, A.; Ifrah, N.; de Witte, T.;
Corringham, R.; James, J.; Lilienfeld, D.; Leo, E.; Trikha, M.; Levis, M.
A Phase II Open-Label, AC220 Monotherapy Efficacy (ACE) Study in
Patients with Acute Myeloid Leukemia (AML) with FLT3-ITD
1001
dx.doi.org/10.1021/ml300214g | ACS Med. Chem. Lett. 2012, 3, 997−1002